JPMorgan Chase raised its price target on AbbVie (ABBV) from $280 to $285, Morgan Stanley from $278 to $296, and Canaccord Genuity from $282 to $290. Additionally, Leerink Partners raised its price target on Agios Pharmaceuticals (AGIO) from $62 to $73.